New hope for hard-to-treat colon cancer? study tests ompenaclid combo
Disease control
Terminated
This study tested whether adding ompenaclid to standard chemotherapy (FOLFIRI plus bevacizumab) could shrink tumors in people with advanced colorectal cancer that has a RAS gene mutation. The trial planned to enroll 76 adults whose cancer had progressed after one prior treatment.…
Phase: PHASE2 • Sponsor: Inspirna, Inc. • Aim: Disease control
Last updated May 17, 2026 04:01 UTC